Instituto Rosenbusch (BUE:ROSE) Earnings Power Value (EPV): ARS-354.87 (As of Dec25)


BUE:ROSE Instituto Rosenbusch SA BUE:ROSE
39 GF Score
Price ARS164.00
GF Value ARS61.70
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Instituto Rosenbusch Earnings Power Value (EPV)?

Instituto Rosenbusch BUE:ROSE +1.23% 39 Earnings Power Value (EPV) is ARS-354.87 as of Dec25. GuruFocus rates BUE:ROSE with a GF Score™ of 39/100 and a GF Value™ of ARS61.70 (Significantly Overvalued). The stock has 4 warning signs investors should review.

As of Dec25, Instituto Rosenbusch's earnings power value is ARS-354.87. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.


Instituto Rosenbusch  (BUE:ROSE) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.


Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.


Instituto Rosenbusch Earnings Power Value (EPV) Related Terms


Instituto Rosenbusch Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Instituto Rosenbusch's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Instituto Rosenbusch Earnings Power Value (EPV) Chart

Instituto Rosenbusch Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -13.52 -64.27 -166.55 -157.07 -354.87

Instituto Rosenbusch Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Earnings Power Value (EPV) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -157.07 -207.95 -254.74 -315.16 -354.87

BUE:ROSE vs ZTS, UTHR, VTRS: Earnings Power Value (EPV) Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Instituto Rosenbusch's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Instituto Rosenbusch Earnings Power Value (EPV) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Instituto Rosenbusch's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Instituto Rosenbusch's Earnings Power Value (EPV) falls into.


BUE:ROSE
39GF Score
Instituto Rosenbusch SA BUE:ROSE
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Instituto Rosenbusch Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

Instituto Rosenbusch's "Earning Power" Calculation:

Average of Last 20 Quarters Last Quarter
Revenue 6,335
DDA 52
Operating Margin % -24.66
SGA * 25% 204
Tax Rate % 7.99
Maintenance Capex 46
Cash and Cash Equivalents 712
Short-Term Debt 519
Long-Term Debt 931
Shares Outstanding (Diluted) 43

1. Start with "Earnings" not including accounting adjustments (one-time charges not excluded unless policy has changed). "Earnings" are "Operating Income.

2. Look at average margins over a business/Industry cycle: Average Operating Margin = -24.66%

To normalize margins and eliminate the effects on profitability of valuing the firm at different points in the business cycle, it is usually best to take a long-term average of operating margins. Ideally this would be as long as 10 years and include at least one economic downturn. However, since most of companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year margin.

3. Multiply average margins by sustainable revenues and then adjust for maintenance SGA. This yields "normalized" EBIT:

To be conservative, GuruFocus uses an average of the 5 year revenues as the sustainable revenue.
EPV analysis recognises that part of SG&A expenditure is made to maintain and replace the existing assets, while part is made to grow sales. Since EPV is only interested in what it costs a going concern to maintain its existing asset base, it adds back a percentage of SG&A (between 15% and 50% - this is a matter of judgment and industry knowledge) to make up for the fact that some of this expenditure went to fund growth and shouldn't be accounted for. To start off, we assume 25% for the sake of prudence.
Sustainable Revenue = ARS6,335 Mil, Average Operating Margin = -24.66%, Average Adjusted SGA = 204,
therefore "Normalized" EBIT = Sustainable Revenue * Average Operating Margin + Average Adjusted SGA = 6,335 * -24.66% +204 = ARS-1358.947665935 Mil.

4. Multiply by one minus Average Tax Rate (NOPAT):

Same as average operating margin calculation, GuruFocus takes an average of the 5 years tax rates.
Average Tax Rate = 7.99%, and "Normalized" EBIT = ARS-1358.947665935 Mil,
therefore After-tax "Normalized" EBIT = "Normalized" EBIT * ( 1 - Average Tax Rate ) = -1358.947665935 * ( 1 - 7.99% ) = ARS-1250.3065947818 Mil.

5. Add back Excess Depreciation (after tax at 1/2 average tax rate). This yields "normalized" Earnings:

Excess Depreciation = Average DDA * % of Excess Depreciation (after tax at 1/2 average tax rate) = 52 * 0.5 * 7.99% = ARS2.0941193025 Mil.
"Normalized" Earnings = After-tax "Normalized" EBIT + Excess Depreciation = -1250.3065947818 + 2.0941193025 = ARS-1248.2124754793 Mil.

6. Adjusted for Maintenance Capital Expenditure:

First, calculate the revenue change regarding to the previous year. If the revenue decreased from the previous year, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous year, then calculate the percentage of Net PPE as of corresponding Revenue.
Third, calculate Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - percentage of Net PPE as of corresponding Revenue * revenue increase.
Fourth, GuruFocus uses an average of the 5 year maintenance capital expenditures as maintenance CAPEX.
Instituto Rosenbusch's Average Maintenance CAPEX = ARS46 Mil *.
* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

7. Investors require a return of "WACC" for the risk they are taking: WACC = 9%

8. Instituto Rosenbusch's current cash and cash equivalent = ARS712 Mil.
Instituto Rosenbusch's current interest bearing debt = Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation = 931 + 519 = ARS1450.004 Mil.
Instituto Rosenbusch's current Shares Outstanding (Diluted Average) = 43 Mil.

Instituto Rosenbusch's Earnings Power Value (EPV) for Dec25 is calculated as:

EPV = ( ( Norm. Earnings-Maint. CAPEX *) / WACC + CashandEquiv - Int. Bearing Debt ) / Shares Outstanding (Diluted Average)
= ( ( -1248.2124754793 - 46)/ 9%+712-1450.004 )/43
=-354.87

Margin of Safety (EPV)=( Earnings Power Value (EPV)-Current Price )/Earnings Power Value (EPV)
=( -354.86916952456-164.00 )/-354.86916952456
= N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

What does a Earnings Power Value (EPV) of ARS-354.87 mean?
Instituto Rosenbusch (BUE:ROSE) has a Earnings Power Value (EPV) of ARS-354.87 as of Dec25. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Instituto Rosenbusch and its competitors.
Is Instituto Rosenbusch's Earnings Power Value (EPV) too high?
Instituto Rosenbusch's current Earnings Power Value (EPV) is ARS-354.87. Overall, Instituto Rosenbusch has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Instituto Rosenbusch's Earnings Power Value (EPV) compare to ZTS and UTHR?
Instituto Rosenbusch's Earnings Power Value (EPV) of ARS-354.87 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Drug Manufacturers company?
A good Earnings Power Value (EPV) depends on the Drug Manufacturers industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Instituto Rosenbusch and its competitors. Instituto Rosenbusch's current Earnings Power Value (EPV) is ARS-354.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Instituto Rosenbusch stock overvalued right now?
Based on GuruFocus' analysis, Instituto Rosenbusch (BUE:ROSE) is currently considered Significantly Overvalued. The stock's GF Value™ is ARS61.70, compared to a current price of ARS164.00 — trading 165.8% above its estimated fair value. The current Earnings Power Value (EPV) is ARS-354.87. Instituto Rosenbusch's overall GF Score™ is 39/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Instituto Rosenbusch (BUE:ROSE), the current Earnings Power Value (EPV) is ARS-354.87 as of Dec25. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Instituto Rosenbusch (BUE:ROSE) Overvalued in 2026?

Based on GuruFocus' analysis, Instituto Rosenbusch stock appears to be overvalued. The current stock price of ARS164.00 is trading 165.8% above its estimated GF Value™ of ARS61.70. GuruFocus considers Instituto Rosenbusch to be Significantly Overvalued.

Key valuation signals for BUE:ROSE:

  • Earnings Power Value (EPV): ARS-354.87
  • GF Value™: ARS61.70 vs. price of ARS164.00 (165.8% above fair value)
  • GF Score™: 39/100 with 4 warning signs

No single metric tells the full story. See the BUE:ROSE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Instituto Rosenbusch Business Description

Address Hipolito Yrigoyen 1628, Buenos Aires, ARG, C1089AAF
Instituto Rosenbusch SA is a pharmaceutical company based in Argentina. The company is engaged in the processing and industrialization of biological, chemical, pharmaceutical products of any kind, nature or destination, preferably for veterinary use or intended to combat pests and diseases of the agricultural exploitation. The company has line of products such as Biologicals and pharmaceuticals. Biologicals offer Campy 3, Cultivac 6M and Bovine Antibrucelosis. Pharmaceuticals offer Diclosan A Intrammamary, Diclosan S Intrammamary and Mastilina V-S.
39GF Score

Get the complete analysis for BUE:ROSE

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS164.00
Price
ARS61.70
GF Value